Lv2
180 积分 2024-12-31 加入
Ianalumab plus Eltrombopag in Immune Thrombocytopenia
25天前
已完结
Bulumtatug Fuvedotin (BFv, 9MW2821), a next-generation Nectin-4 targeting antibody–drug conjugate, in patients with advanced solid tumors: a first-in-human, open-label, multicenter, phase I/II study
1个月前
已完结
Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma
1个月前
已完结
QT Prolongation Risk of Antibody–Drug Conjugates
1个月前
已完结
Improving Dose-Optimization Processes Used in Oncology Drug Development to Minimize Toxicity and Maximize Benefit to Patients
1个月前
已完结
Exposure-Response–Based Multiattribute Clinical Utility Score Framework to Facilitate Optimal Dose Selection for Oncology Drugs
1个月前
已完结
Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma
2个月前
已完结
Practical guide to concentration-QTc modeling: a hands-on tutorial
2个月前
已完结
Trastuzumab rezetecan, a HER2-directed antibody–drug conjugate, in patients with advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): phase 2 results from a multicentre, single-arm study
4个月前
已完结
皖公网安备34019202002308
